Avenue therapeutics, inc. (ATXI)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16
ASSETS
Current Assets:
Cash and cash equivalents

6,574

8,745

8,741

10,455

29,448

2,671

4,804

8,940

14,963

11,782

16,050

-

-

197

Short-term investments

-

-

5,000

5,000

-

-

0

0

0

10,000

10,000

-

-

0

Deferred financing costs

-

-

61

61

61

1,702

-

-

-

0

-

-

-

-

Prepaid expenses and other current assets

122

170

76

161

254

152

459

496

310

388

-

-

-

0

Cash

-

-

-

-

-

-

-

-

-

-

-

34,683

0

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

126

22

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

234

-

Total Assets

6,696

8,915

13,878

15,677

29,763

4,525

5,263

9,436

15,273

22,170

26,176

34,705

234

197

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses

790

1,101

1,901

1,728

9,326

4,669

2,098

4,234

5,753

2,737

1,914

826

868

506

Accounts payable and accrued expenses - related party

133

14

16

45

86

487

371

185

167

53

76

-

-

1,348

Licenses payable

-

1,000

-

-

-

0

-

-

-

-

-

-

-

-

Accrued expenses - related party

-

-

-

-

-

-

-

-

-

-

-

167

1,568

-

Interest payable

-

-

-

-

-

-

-

-

-

-

0

56

5

57

Accrued interest - related party

-

-

-

-

-

-

-

-

-

-

0

120

404

346

Notes payable - related party

-

-

-

-

-

-

-

-

-

-

0

3,486

2,919

2,848

NSC notes payable, short-term

-

-

-

-

-

-

-

-

-

-

0

2,500

1,750

1,000

Derivative warrant liability

-

-

-

-

-

-

-

-

-

-

0

0

311

314

Total current liabilities

923

2,115

1,917

1,773

9,412

5,156

2,469

4,419

5,920

2,790

1,990

7,155

7,825

6,419

Convertible notes payable, at fair value

-

-

-

-

-

-

-

-

-

-

0

0

204

200

NSC notes payable, long-term (net of debt discount of $0 and $174, respectively)

-

-

-

-

-

-

-

-

-

-

0

394

1,109

1,826

Total Liabilities

923

2,115

1,917

1,773

9,412

5,156

2,469

4,419

5,920

2,790

1,990

7,549

9,138

8,445

Commitments and Contingencies

-

-

-

-

-

-

0

0

0

-

0

-

0

0

Stockholders' Equity
Common shares, 16,682,803 and 16,682,190 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

2

2

2

2

2

1

1

1

1

1

1

1

1

1

Common stock issuable, 0 and 273,837 shares as of December 31, 2018 and 2017, respectively

-

-

-

-

-

-

0

0

0

1,103

0

0

0

49

Additional paid-in capital

75,130

74,915

74,661

74,362

73,827

41,577

41,083

40,711

40,390

38,937

38,603

38,625

159

105

Accumulated deficit

-69,359

-68,117

-62,702

-60,460

-53,478

-42,209

-38,290

-35,695

-31,038

-20,661

-14,418

-11,470

-9,064

-8,403

Total Stockholders' Equity

5,773

6,800

11,961

13,904

20,351

-631

2,794

5,017

9,353

19,380

24,186

27,156

-8,904

-8,248

Total Liabilities and Stockholders' Equity

6,696

8,915

13,878

15,677

29,763

4,525

5,263

9,436

15,273

22,170

26,176

34,705

234

197

Series A Preferred Stock [Member]
Preferred Stock ($0.0001 par value), 2,000,000 shares authorized Class A Preferred Stock, 250,000 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

0

0

0

0

0

0

-

-

-

0

-

-

-

-